ClinicalTrials.gg
CompletedNCT00556894Updated Mar 29, 2018Results posted

Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

A Phase 2 interventional study of CF101 and Placebo in Rheumatoid Arthritis, sponsored by Can-Fite BioPharma. Completed at 26 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-29.

Sponsored by Can-Fite BioPharma · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
253
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 118 studies in Arthritis, Rheumatoid with a site in Ukraine — 4 open to participants now, 8 under way, 1 of them phase 3. Arthritis, Rheumatoid · Ukraine.

Enrollment
82nd of 115
253 · median 409
Started
2008
with 5 others
Phase 2
56 of 118
1 open now
Registered
19th of 118
by date

Among the 118 studies in Arthritis, Rheumatoid with a site in Ukraine, this one is the 82nd largest by enrollment of the 115 interventional ones that give a count, is one of 6 that started in 2008, is one of 56 in phase 2, and was the 19th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 118 studies in Arthritis, Rheumatoid with a site in Ukraine are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Arthritis, Rheumatoid with a site in Ukraine, or all of them as a file.
02

Study summary

This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.

Read the detailed description

This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, dose-finding study in which patients with active RA despite receiving methotrexate for at least 6 months (at unchanged doses for >=2 months) will be randomized to the addition of either CF101 0.1 mg, CF101 1 mg, or placebo given orally q12h for 12 weeks. Screening examinations will occur within 1 month prior to dosing. Washout of other disease-modifying antirheumatic drugs (DMARDs) (with the exception of hydroxychloroquine), including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be stable for >=1 month prior to dosing and remain so during protocol participation. Disease activity will be assessed using swollen and tender joint counts, physician and patient global assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, and 12.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ages 18-75 years
  • Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324; refer to Appendix 1. diagnostic criteria for Rheumatoid Arthritis)
  • Not bed- or wheelchair-bound
  • Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND either: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the for the central reference laboratory
  • Treatment with weekly oral or parenteral methotrexate for >=6 months prior to baseline
  • Methotrexate route of administration has been unchanged for >=2 months prior to baseline
  • Dose of methotrexate has been stable at 15-25 mg/week for >=2 months, and is expected to remain stable throughout the study; the stable dose of methotrexate may alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose
  • If taking hydroxychloroquine or chloroquine, administration duration has been for >=3 months and dose has been stable for >=2 months prior to baseline
  • If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to baseline, and will remain unchanged during protocol participation
  • If taking an oral , dose is \<10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the stabilization period, and will remain stable through the stabilization and entire treatment and follow-up period
  • Negative screening serum pregnancy test for female patients of
  • Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)

Exclusion criteria

Exclusion Criteria:

  • Receipt of any of the following for at least a 1 month stabilization period prior to dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra
  • Receipt of etanercept for at least a 6 week period prior to dosing
  • Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior to dosing
  • Receipt of leflunomide for at least a 2 month period prior to screening, unless patient has undergone cholestyramine at least 1 month prior to dosing
  • Receipt of cyclophosphamide for at least a 6 month period prior to dosing
  • Receipt of rituximab at any previous time
  • Participation in a previous trial CF101 trial
  • Use of oral >10 mg of prednisone, or equivalent, per day
  • Change in NSAID dose level for 1 month prior to dosing
  • Change in oral corticosteroid dose level during the 1 month prior to, or during, the stabilization period vChange in hydroxychloroquine or chloroquine dose level during the 2 months prior to, or during, the stabilization period
  • Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to, or during, the stabilization period
  • Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of heart disease; other clinically significant findings on screening (ECG)
  • level \<9.0 gm/dL at the screening visit
  • count \<125,000/mm3 at the screening visit
  • White blood cell count \<3000/mm3 at the screening visit
  • Serum creatinine level outside the central laboratory's normal limits at the screening visit
  • Liver aminotransferase ( and/or AST) levels greater than 1.25 times the central laboratory's at the screening visit
  • Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
253 participants (actual)

Study arms

  • Experimental
    CF101 0.1 mg

    CF101 0.1 mg was given orally q12h

    Drug: CF101

  • Experimental
    CF101 1 mg

    CF101 1 mg was given orally q12h

    Drug: CF101

  • Placebo comparator
    Placebo

    Matched placebo was given orally q12h

    Drug: Placebo

Interventions

  • DrugCF101

    orally q12h

    Also known as: IB-MECA

  • DrugPlacebo

    orally q12h

06

What researchers measure

Primary outcomes

  1. ACR20 at Week 12

    Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria

    Time frame: 12 weeks

Secondary outcomes

  1. ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters

    ACR20/50/70 responses over time (intent-to-treat \[ITT\], last observation carried forward \[LOCF\]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses

    Time frame: 12 weeks

07

Results

Posted Mar 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneCF101 0.1mgCF101 1mgPlacebo
Started828784
Completed666865
Not completed161919
Withdrew: Adverse event233
Withdrew: Death100
Withdrew: Regulatory decision in bulgaria101413
Withdrew: Change in therapy212
Withdrew: Withdrawal by subject111

Outcome measures

PrimaryACR20 at Week 12

Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria

Time frame:
12 weeks
Reported as:
Number · participants
ACR20 at Week 12
participantsCF101 0.1mgCF101 1mgPlacebo
ACR20 at Week 12293433
SecondaryACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters

ACR20/50/70 responses over time (intent-to-treat \[ITT\], last observation carried forward \[LOCF\]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses

Time frame:
12 weeks

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CF101 0.1mg—3/82 (3.7%)2/82 (2.4%)
CF101 1mg—2/87 (2.3%)5/87 (5.7%)
Placebo—3/84 (3.6%)1/84 (1.2%)
Most frequent serious events
Most frequent serious events
EventCF101 0.1mgCF101 1mgPlacebo
Nausea and DiarrhoeaGastrointestinal disorders1/822/870/84
PancytopeniaBlood and lymphatic system disorders1/820/870/84
Alanine aminotransferase and Aspartate aminotransferase increasedInvestigations1/821/871/84
Microcytic anemiaBlood and lymphatic system disorders0/820/871/84
Eyelid oedemaEye disorders0/820/871/84
Most frequent other events
Most frequent other events
EventCF101 0.1mgCF101 1mgPlacebo
NauseaGastrointestinal disorders2/825/871/84

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CF101 0.1mgCF101 1mgPlaceboTotal
<=18 years0000
Between 18 and 65 years666969204
>=65 years16181549
Age, Continuous
Age, Continuous(years)CF101 0.1mgCF101 1mgPlaceboTotal
Median55 (24 to 75)54 (25 to 75)54 (33 to 73)54 (24 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)CF101 0.1mgCF101 1mgPlaceboTotal
Female686471203
Male14231350
Region of Enrollment
Region of Enrollment(participants)CF101 0.1mgCF101 1mgPlaceboTotal
Serbia22202062
Ukraine22262674
Israel99826
Bulgaria29323091
08

Study locations

26 sites
  • Clinic of Rheumatology at MHAT 'Sveti Georgi'
    Plovdiv, 4002, Bulgaria
  • Clinic of Rheumatology at MHAT 'Sveti Ivan Rilski'
    Sofia, 1612, Bulgaria
  • Clinic of internal diseases at NMTH 'Tzar Boris Treti'
    Sofia, Bulgaria
  • Second Clinic of Internal Diseases at MHAT 'Stara Zagora'
    Stara Zagora, 6000, Bulgaria
  • Clinic of Rheumatology at MHAT 'Sveta Marina' - Varna
    Varna, 9010, Bulgaria
  • University Hospital Hradec Kralove
    Hradec Kralove, 50005, Czechia
  • Institute of Rheumatology
    Prague, 12850, Czechia
  • Rheumotology Out-patient Clinic
    Zlin, 76001, Czechia
  • Haemek Medical Center
    Afula, Israel
  • Barzilai Medical Center
    Ashkelon, 78278, Israel
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Hadassah Har-Hazofim Medical Center
    Jerusalem, Israel
  • Meir Medical Center
    Kfar-Saba, 44281, Israel
  • Wojewodzki Szpital Zespolony w Elblagu
    Elblag, 82300, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej
    Lublin, 20607, Poland
  • Wojewodzki Zespol Reumatologiczny w Sopocie
    Sopot, 81967, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 P.A.M. w Szczecinie
    Szczecin, 71252, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej "NASZ LEKARZ"
    Torun, 87100, Poland
  • Institute of Rheumatology - Belgrade
    Belgrade, 11000, Serbia
  • Institute for Prevention, Treatment, and Rehabilitation of Rheumatoid and Cardiovascular Diseases Niska Banja
    Niska Banja, 18205, Serbia
  • Central Municipal Clinical Hospital nº1
    Donetsk, 83114, Ukraine
  • Kyiv Central Municipal Hospital
    Kiev, 01023, Ukraine
  • City Clinical Hospital N12
    Kiev, 01103, Ukraine
  • National Scientific Centre of AMS of Ukraine
    Kiev, 03680, Ukraine
  • O.O. Bogomolets National Medical University
    Kiev, 04053, Ukraine
  • Vinnitsya Regional Clinical Hospital
    Vinnycia, 21018, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 6 years after primary completion. A results delay was requested in Jun 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2007
First posted
Nov 12, 2007
Start
Feb 2008
Primary completionActual
Mar 2009
CompletionActual
Apr 2009
Results delay requested
Jun 14, 2011
Results first posted
Mar 9, 2015
Last update
Mar 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00556894
Lead sponsor
Can-Fite BioPharma
Responsible party
Sponsor
First posted
Nov 12, 2007
Start date
Feb 2008
Primary completion
Mar 2009
Completion
Apr 2009
Results posted
Mar 9, 2015
Last update
Mar 29, 2018

Study contacts

Michael H Silverman, MD
study director · BioStrategics Consulting Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CF101

Start the discussion